Lovastatin

Generic Name
Lovastatin
Brand Names
Advicor, Altoprev
Drug Type
Small Molecule
Chemical Formula
C24H36O5
CAS Number
75330-75-5
Unique Ingredient Identifier
9LHU78OQFD
Background

Lovastatin, also known as the brand name product Mevacor, is a lipid-lowering drug and fungal metabolite derived synthetically from a fermentation product of Aspergillus terreus. Originally named Mevinolin, lovastatin belongs to the statin class of medications, which are used to lower the risk of cardiovascular disease and manage abnormal lipid levels by inh...

Indication

Lovastatin is indicated to reduce the risk of myocardial infarction, unstable angina, and the need for coronary revascularization procedures in individuals without symptomatic cardiovascular disease, average to moderately elevated total-C and LDL-C, and below average HDL-C. It is indicated as an intervention alternative in individuals presenting dyslipidemia...

Associated Conditions
Apolipoprotein, Cholesterol, LDL, Coronary Artery Atherosclerosis, Coronary Revascularization, Myocardial Infarction, Peripheral Arterial Disease (PAD), Unstable Angina Pectoris, Elevation of serum triglyceride levels, Total cholesterol increased
Associated Therapies
-
Clinical Trials
Related News

Lovastatin as a Potential Modulator of Apoptosis in Chronic Obstructive Pulmonary Disease (COPD)

First Posted Date
2008-06-19
Last Posted Date
2021-01-19
Lead Sponsor
National Jewish Health
Target Recruit Count
30
Registration Number
NCT00700921
Locations
🇺🇸

National Jewish Medical and Research Center, Denver, Colorado, United States

Evaluation of Lovastatin in Severe Persistent Asthma

Phase 1
Withdrawn
Conditions
Severe Persistent Asthma
Interventions
Drug: Placebo
Drug: Lovastatin
First Posted Date
2008-06-04
Last Posted Date
2013-06-21
Lead Sponsor
University of Chicago
Registration Number
NCT00689806

A Study of the Proper Dosage of Lovastatin and Docetaxel for Patients With Cancer

Phase 1
Terminated
Conditions
Any Cancer
Breast Cancer
Interventions
Drug: Lovastatin
Drug: Docetaxel
First Posted Date
2008-01-02
Last Posted Date
2018-10-19
Lead Sponsor
Susan L Roeder
Target Recruit Count
9
Registration Number
NCT00584012
Locations
🇺🇸

Holden Comprehensive Cancer Center, Iowa City, Iowa, United States

A Phase II Study of Interaction of Lovastatin and Paclitaxel For Patients With Refractory or Relapsed Ovarian Cancer

Phase 2
Terminated
Conditions
Ovarian Cancer
Interventions
Drug: Paclitaxel
Drug: Lovastatin
First Posted Date
2008-01-02
Last Posted Date
2018-01-05
Lead Sponsor
University of Iowa
Target Recruit Count
11
Registration Number
NCT00585052
Locations
🇺🇸

Holden Comprehensive Cancer Center, Iowa City, Iowa, United States

Dose Escalation Phase I/II Study of Lovastatin With High-Dose Cytarabine for Refractory or Relapsed AML

Phase 1
Terminated
Conditions
Acute Myeloid Leukemia
Interventions
Drug: Cytarabine
Drug: Lovastatin
First Posted Date
2007-12-31
Last Posted Date
2018-01-05
Lead Sponsor
University of Iowa
Target Recruit Count
23
Registration Number
NCT00583102
Locations
🇺🇸

Holden Comprehensive Cancer Center, Iowa City, Iowa, United States

Study of Effectiveness of Lovastatin to Prevent Radiation-Induced Rectal Injury

Phase 2
Completed
Conditions
Prostate Cancer
Interventions
Drug: lovastatin
First Posted Date
2007-12-27
Last Posted Date
2016-11-18
Lead Sponsor
Virginia Commonwealth University
Target Recruit Count
73
Registration Number
NCT00580970
Locations
🇺🇸

Hunter Holmes McGuire Veterans Administration Medical Center, Richmond, Virginia, United States

🇺🇸

Massey Cancer Center/Virginia Commonwealth University, Richmond, Virginia, United States

🇺🇸

Southside Regional Medical Center, Richmond, Virginia, United States

Lovastatin in Treating Patients At High Risk of Melanoma

First Posted Date
2007-04-19
Last Posted Date
2014-10-31
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
80
Registration Number
NCT00462280
Locations
🇺🇸

University of California Medical Center At Irvine-Orange Campus, Orange, California, United States

🇺🇸

Huntsman Cancer Institute, Salt Lake City, Utah, United States

🇺🇸

H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States

Trial to Evaluate the Safety of Lovastatin in Individuals With Neurofibromatosis Type I (NF1)

Phase 1
Completed
Conditions
Neurofibromatosis 1
Interventions
Drug: placebo pill
Drug: Lovastatin
First Posted Date
2006-07-14
Last Posted Date
2016-11-22
Lead Sponsor
University of California, Los Angeles
Target Recruit Count
44
Registration Number
NCT00352599
Locations
🇺🇸

Semel Institute for Neuroscience and Human Behavior, Los Angeles, California, United States

Lovastatin for the Treatment of Mildly Active Rheumatoid Arthritis

Phase 2
Terminated
Conditions
Rheumatoid Arthritis
Interventions
Drug: Placebo
Drug: Lovastatin
First Posted Date
2006-03-15
Last Posted Date
2022-09-07
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Target Recruit Count
64
Registration Number
NCT00302952
Locations
🇺🇸

University of Rochester, Rochester, New York, United States

🇺🇸

Carolina Bone and Joint, Charlotte, North Carolina, United States

🇺🇸

Altoona Center for Clinical Research, Duncansville, Pennsylvania, United States

and more 12 locations

Phase 2 Study of Lovastatin as Breast Cancer Chemoprevention

Phase 2
Terminated
Conditions
Breast Cancer
Interventions
Drug: Lovastatin
First Posted Date
2006-02-02
Last Posted Date
2017-03-09
Lead Sponsor
Stanford University
Target Recruit Count
30
Registration Number
NCT00285857
Locations
🇺🇸

Stanford University Cancer Center, Stanford, California, United States

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy